By Arasu Kannagi Basil (Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

An international team of scientists have discovered that soap could be important to helping our understanding of complex ...

Here's what's new in Bay Area biz news to start your workweek: tech stocks on wild ride, empty S.F. office buildings, copper ...